Pixium Vision (OTCMKTS:PXMVF) vs. Akoya Biosciences (NASDAQ:AKYA) Financial Contrast

Pixium Vision (OTCMKTS:PXMVF) and Akoya Biosciences (NASDAQ:AKYA) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, institutional ownership, profitability, valuation and earnings.

Insider & Institutional Ownership

79.4% of Akoya Biosciences shares are held by institutional investors. 8.5% of Akoya Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Pixium Vision and Akoya Biosciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Pixium Vision	N/A	N/A	N/A
Akoya Biosciences	-65.53%	-110.24%	-36.14%

Analyst Recommendations

This is a breakdown of current recommendations for Pixium Vision and Akoya Biosciences, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pixium Vision	0	0	0	0	N/A
Akoya Biosciences	0	1	6	0	2.86

Akoya Biosciences has a consensus target price of $9.07, indicating a potential upside of 93.42%. Given Akoya Biosciences’ higher possible upside, analysts plainly believe Akoya Biosciences is more favorable than Pixium Vision.

Valuation and Earnings

This table compares Pixium Vision and Akoya Biosciences’ top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pixium Vision	N/A	N/A	N/A	N/A	N/A
Akoya Biosciences	$96.63 million	2.39	-$63.32 million	($1.48)	-3.17

Pixium Vision has higher earnings, but lower revenue than Akoya Biosciences.

Summary

Akoya Biosciences beats Pixium Vision on 5 of the 8 factors compared between the two stocks.

About Pixium Vision

Pixium Vision SA, a bioelectronics and brain machine interface technology company, specialized in neuromodulation application. It develops PRIMA System, a bionic vision system for patients with vision loss due to retinal degeneration caused by the dry atrophic form of Age-related Macular Degeneration (AMD); and to treat blindness, which replace the normal physiological function of the eye's photoreceptor cells by electrically stimulating the nerve cells of the inner retina, which then transmit the stimulation to the brain via the intermediary of the optic nerve. The company has collaboration agreements with Stanford University in California, Institute of Ocular Microsurgery in Barcelona, Institut de la Vision in Paris, Moorfields Eye Hospital in London, University Hospital in Bonn, and UPMC in Pittsburgh. Pixium Vision SA was founded in 2011 and is based in Paris, France.

About Akoya Biosciences

Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow. It also provides PhenoCycler and PhenoImager reagents; and biopharma services. In addition, the company offers analysis software partnerships ecosystem; inForm Tissue, an automated image analysis software package for accurately visualizing and quantifying biomarkers in tissue sections; Phenoptr, which provides functions that consolidate and analyze output tables created by inForm software; and phenoptrReports, a software that generates shareable reports and visualizations based on the phenoptr output in an intuitive front-end GUI. The company was incorporated in 2015 and is headquartered in Marlborough, Massachusetts.